Global Acute Coronary Syndrome industry

  • April 2010
  • -
  • Global Industry Analysts

This report analyzes the global market for Acute Coronary Syndrome Therapeutics in US$ Million. Annual estimates and forecasts are provided for the period 2006 through 2015. The report profiles 60 companies including Abbott Laboratories Inc., AstraZeneca, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company Limited, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Inverness Medical Innovations, Inc., Merck & Co., Inc., Medicure Inc., Novartis AG, Pfizer, Inc., Wyeth, Sanofi-Aventis SA, Schering-Plough Corp., Siemens Healthcare Diagnostics, Inc., Takeda Pharmaceutical Company Limited, and The Medicines Company. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Table Of Contents


ACUTE CORONARY SYNDROME MCP-6355
A GLOBAL MARKET REPORT


CONTENTS


I. INTRODUCTION, METHODOLOGY and PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation and Reporting Level I-3
Quantitative Techniques and Analytics I-3
Product Definitions and Scope of Study I-3


II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW II-1
Acute Coronary Syndrome - A Primer II-1
Table 1: World Recent Past, Current and Future Analysis for
Acute Coronary Syndrome Therapeutics Market - Annual Revenues
in US$ Million for Years 2006 through 2015 (includes
corresponding Graph/Chart) II-1
Global ACS Drugs Market Scenario II-2
Table 2: Leading ACS Drugs with Global Sales Revenues (in
US$ billion) for the Year 2008 (includes corresponding
Graph/Chart) II-3

Table 3: Select Leading Myocardial Infarction Drugs
Worldwide: Value Sales for 2007 and 2008 in US$ Million
(includes corresponding Graph/Chart) II-4

Table 4: Select Leading Coronary Artery Disease/
Atherosclerosis Drugs Worldwide: Value Sales for 2007 and
2008 in US$ Million (includes corresponding Graph/Chart) II-4

Table 5: Select Leading Angina Drugs Worldwide: Value Sales
for 2007 and 2008 in US$ Million (includes corresponding
Graph/Chart) II-5
Table 6: Estimated Number of Products Available for Select
ACS Indications (includes corresponding Graph/Chart) II-5
Key Market Drivers and Constraints II-5
Antithrombotics - The Driving Force in Future II-5
Combination Products II-6
Drug Delivery Technologies II-6
Fast and Accurate Diagnosis - Reduce Unnecessary Healthcare
Costs II-6
Patent Expiry of Best Selling Products: A Key Concern for
the Industry II-7
List of Leading Cardiovascular Drugs on the Verse of Patent
Expiry II-7
Lack of Product Differentiation II-8
Fewer Product Introductions II-8
Market Characteristics II-8
United States and Europe - Far Ahead and Far More Powerful II-8
Anticoagulants - Remarkable Drug Development Potential II-8
Anticoagulants to Lose ACS Indications to Antiplatelets II-9
Novel Anticoagulants to Drive Atrial Fibrillation Drug Market II-9
Protein Therapy Research Promises Cardiovascular Disease
Treatment II-9
Future Directions: Shape Of Things To Come II-10
Table 7: Estimated Number of Pipeline Products by Select ACS
Indication (includes corresponding Graph/Chart) II-10
Table 8: Estimated Number of Candidates in Development Phase
by Select ACS Indication (includes corresponding Graph/
Chart) II-11
List of Cardiovascular (including ACS) Pipeline Products in
Phase III Development (as of March 2007) II-11
List of Cardiovascular (including ACS) Pipeline Products in
Phase II Development (as of March 2007) II-12
List of Cardiovascular (including ACS) Pipeline Products in
Phase I Development (as of March 2007) II-14
List of Cardiovascular (including ACS) Pipeline Products in
Pre-clinical Development (as of March 2007) II-15
Pharmaceutical Industry: A Review of the Current Scenario II-16
Industry Framework II-16
Consolidation Gets Underway II-16
Patent Expiries Giving Way to Generic Drugs II-17
Developing Countries Hold the Key to Future Growth II-17
Table 9: World Pharmaceutical Industry (2007): BRIC Nations
(Brazil, Russia, India and China), and United States Ranked by
Percentage Growth (includes corresponding Graph/Chart) II-17
Impact of the Recession: An Unequivocal Review II-18

2. DISEASE OVERVIEW II-19
Definition And Pathophysiology II-19
Cardiac Circulation and Conduction II-19
Acute Coronary Syndrome - A Definition II-19
Underlying Cause of ACS II-19
Unstable Angina II-20
Causes and Symptoms II-20
Treatment Options II-20
Myocardial Infarction (MI) II-20
Non-ST-Segment Elevated Myocardial Infarction (NSTEMI) II-21
ST-Segment Elevated Myocardial Infarction (STEMI) II-21
Chain Reaction After an Event of MI II-21
Action Plan after an Event of MI II-21
Causes and Symptoms II-21
Drug Treatment Options II-22
Epidemiology II-22
Cardiovascular Diseases II-22
Table 10: Region-Wise Incidence and Prevalence of
Cardiovascular Diseases in 2006 (includes corresponding
Graph/Chart) II-23
Factors Responsible for Coronary Diseases II-23
Uncontrollable Risk Factors II-24
Ageing Global Population II-24
Table 11: World Demographic Trends: People Over 65 as a
Percentage of Total Population by Geographic Region- US,
Canada, Japan, Europe, Asia-Pacific, and Latin America for
years 2000, 2008, 2010, and 2020 (includes corresponding
Graph/Chart) II-24
Heredity II-24
Gender II-25
Diabetes II-25
Controllable Risk Factors II-25
High Blood Cholesterol II-25
HDL Cholesterol II-25
HDL Cholesterol Levels and Potential Risk of
Cardiovascular Disease II-26
LDL Cholesterol II-26
LDL Cholesterol Levels and Potential Risk of
Cardiovascular Disease II-26
Triglyceride Levels II-26
Triglyceride Level and Potential Risk of Cardiovascular
Disease II-26
Smoking II-27
Changing Habits and Lifestyle II-27
High Blood Pressure II-27
Causative Risk Factors II-27
Stress and Anger II-27
Obesity II-27
Disease Investigation And Diagnosis II-28
ECG II-28
Exercise ECG (ECG Stress Testing) II-28
Test Procedure and Precautions II-29
Blood Tests (for the Presence of Cardiac Biomarkers) II-29
Myocardial Infarction Cardiac Biomarkers - Benefits and
Limitations II-30
C-Reactive Protein II-30
Necessity of a Cardiac Marker Assay Test II-31
How it Works? II-31
Need for Early Detection Markers II-31
Strong Demand for Risk Assessment Markers II-32
Invasive Imaging Tests II-32
Coronary Angiography (or Cardiac Angiography) II-32
Test Procedure and Results II-32
Intravascular Ultrasound (IVUS) II-33
Test Procedure and Results II-33
Medication Strategies II-34
Anti-ischemic Agents II-34
Nitrates II-34
Description on Some of the Nitrate Drugs for Acute
Coronary Syndrome II-35
Usage of Nitrates in ACS Indications II-35
Unstable Angina (UA) II-35
Acute Myocardial Infarction (AMI) II-35
b Blockers II-36
List of Indications for Select Beta-blocker Drugs II-36
Calcium Channel Blockers II-36
List of Indications for Select Calcium Channel Blockers II-37
ACE and ACE II Inhibitor Drugs II-37
Angiotensin Converting Enzyme (ACE) Inhibitors II-37
List of Different Types of ACE Inhibitors and Products II-38
Angiotensin II Receptor Antagonists (ACE II or sartans) II-38
List of Different Types of Angiotensin II Receptor
Antagonists and Products II-39
Cholesterol Reducing Drugs II-39
Statins Lead the Way II-39
Emerging Leaders II-40
Table 12: Leading Cholesterol Reducing Drugs Worldwide:
Sales for the years 2004 through 2008 for Lipitor, Crestor
and Vytorin (in US$ Billion) (includes corresponding
Graph/Chart) II-40
Lack of Product Differentiation Mars Prospects II-40
Zocor - The First Statin to Switch to OTC II-41
Patent Expiries of Leading Cholesterol Reducers: 2009 and
Beyond II-41
Anticoagulants II-41
Anticoagulant Drug Classes II-41
Oral Anticoagulants II-41
Warfarin II-42
Coumadin II-42
Injectable Anticoagulants II-42
Heparin II-43
Unfractionated Heparin II-43
Low Molecular Weight Heparin (LMWH) II-44
A Snapshot of Available Anticoagulant Therapies II-44
Antiplatelet Agents II-45
List of Indications for Select Antiplatelet Drugs II-45
Thrombolytics II-45
Key Indications Relating to ACS II-46
Others II-46
Aspirin II-46
Oxygen Supply II-47
Pain Reliving Agents II-47
Revascularization Procedures II-47
Invasive Treatments II-47
Bypass Surgery II-47
Percutaneous Transluminal Coronary Angioplasty (Balloon
Angioplasty) II-47
Coronary Stents II-48
Drug Eluting Stents Steal the Show II-48
Applications of Coronary Stents II-49
Key Stents Delivery Platforms by Select Company II-50
Coronary Stents - Leading Players II-50
Table 13: Leading Players in the Global Coronary Stents
Market (2006-2008) - Percentage Breakdown by Revenues for
Boston Scientific, Johnson and Johnson, Abbott, Medtronic,
and Others (includes corresponding Graph/Chart) II-50
Bare Metal Stents - Leading Players II-51
Table 14: Leading Players in the Global Bare Metal Stents
Market (2006-2008) - Percentage Breakdown by Revenues for
Abbott, Johnson and Johnson, Boston Scientific, Medtronic,
and Others (includes corresponding Graph/Chart) II-51
Drug-Eluting Stents - Leading Players II-52
Table 15: Leading Players in the Global Drug-Eluting Stents
Market (2006-2008) - Percentage Breakdown by Revenues for
Boston Scientific, Johnson and Johnson, Abbott, and Medtronic
(includes corresponding Graph/Chart) II-52
Cell Transplantation - An Emerging Procedure For Chronic
Heart Ailments II-52

3. REGIONAL MARKET OVERVIEW II-53
The United States II-53
Cardiovascular Diseases in the US: A Review II-53
Table 16: The US Disease Statistics for Coronary Heart
Disease (CHD) and Myocardial Infarction (MI) (includes
corresponding Graph/Chart) II-53
AHA Statistics for Coronary Heart Disease II-54
Table 17: The US Prevalence of Coronary Heart Disease (CHD)
as a Percentage of Total Population by Age group and Sex,
in 2005-06 (includes corresponding Graph/Chart) II-54

Table 18: The US Prevalence of Stroke as a Percentage of
Total Population by Age group and Sex, in 2005-06 (includes
corresponding Graph/Chart) II-55
Statistics from NCHS and NHLBI on ‘Death Due to
Cardiovascular Diseases’ II-55
Table 19: Mortality Rate in the US for the Year 2006 by
Cardiovascular Diseases -Percentage Breakdown of Deaths
from Coronary Heart Disease, Stroke, High Blood Pressure,
Heart Failure, Diseases of the Arteries, and Others
(includes corresponding Graph/Chart) II-55

Table 20: Mortality Rate in the US Males for the Year 2005
by Ailment - Heart Diseases, Cancer, Accidents, Chronic
Lower Respiratory Diseases, and Diabetes (includes
corresponding Graph/Chart) II-56

Table 21: Mortality Rate in the US Females for the Year
2005 by Ailment - Heart Diseases, Cancer, Chronic Lower
Respiratory Diseases, Alzheimer’s, and Accidents (includes
corresponding Graph/Chart) II-56
Fall in Number of Deaths due to Heart Diseases and Strokes II-57
Senior Citizens at High Risk for Heart Failure II-57
Baby Boomers Boost Coronary Stent Market II-57
Generics Trigger Price war II-58
Table 22: US Cardiovascular Drugs Market - Total
Prescriptions by Drug Class (in Thousands) for the Years
2008 and 2009 (includes corresponding Graph/Chart) II-58

Table 23: Select Leading Myocardial Infarction Drugs in the
US: Value Sales in US$ Million for the Years 2007 and 2008
(includes corresponding Graph/Chart) II-59

Table 24: Select Leading Coronary Artery Disease/
Atherosclerosis Drugs in the US: Value Sales in US$ Million
for the Years 2007 and 2008 (includes corresponding
Graph/Chart) II-59

Table 25: Select Leading Angina Drugs in the US: Value
Sales in US$ Million for the Years 2007 and 2008 (includes
corresponding Graph/Chart) II-60
Antihyperlipidemics II-60
Table 26: US Cardiovascular Drugs Market for Statins (HMG
CoA-Reductase Inhibitors) - Type of Statin Ranked by Value
Sales in US$ Million for the Year 2007 (includes
corresponding Graph/Chart) II-61

Table 27: US Antihyperlipidemic Drugs Market (2007):
Percentage Share Breakdown of Total Prescriptions by
Leading Drugs (includes corresponding Graph/Chart) II-61
Anticoagulants and Antiplatelets II-62
Table 28: US Anticoagulant Drugs Market (2007): Percentage
Share Breakdown of Total Prescriptions by Leading Product
(includes corresponding Graph/Chart) II-62
Drug Development Pipeline II-63
US Pharmaceutical Sector Scenario II-63
Table 29: US Pharmaceutical Market (2008) - Leading
Pharmaceutical Companies Ranked by Value Sales in US$
Million (includes corresponding Graph/Chart) II-63

Table 30: US Pharmaceutical Market (2007) - Leading
Pharmaceutical Products Ranked by Value Sales in US$
Million (includes corresponding Graph/Chart) II-64

Table 31: US Pharmaceuticals Market (2008) - Leading
Therapeutic Class Ranked by Value Sales in US$ Million
(includes corresponding Graph/Chart) II-64

Table 32: US Cardiovascular Drugs Market (2008) - Leading
Companies Ranked by Cardiovascular Drug Sales in US$
Million (includes corresponding Graph/Chart) II-65
Canada II-65
Leading Drugs in Canada II-65
Table 33: Leading Prescription Drugs in Canada (2006 and 2007)
- Number of Dispensed Prescriptions in Million Scripts for
Lipitor, Synthroid, Norvasc, Asaphen, Pantoloc, Crestor,
Altace, Ratio-Salbutamol Hfa (includes corresponding
Graph/Chart) II-66
Europe II-66
European Cardiovascular Diseases Fact Sheet II-66
Cardiovascular Disease - Risk Factor Profile II-67
The Cardiovascular Disease Cost Burden II-67
Mortality by Heart Attack Declines II-67
EU to Face Health Care Expenditure Challenge Head-on II-68

4. PRODUCT LAUNCHES/APPROVALS/ DEVELOPMENTS II-69
FDA Approves Prasugrel II-69
Efient® (Prasugrel) Obtains Approval by European Commission II-69
The Medicines Company Obtains Approval for Angiox® by
European Union II-70
CV Therapeutics Obtains FDA Approval for New Indication for
Ranexa II-70
BMS and Pfizer Announce APPRAISE-1 Results for Apixaban II-71
Scottish Medicines Consortium Issues Approval for Various Drugs II-71
Schweizerhall Holding AG/Cimex AG to Launch Plavix® (
Clopidogrel) Generic II-71
Response Bags FDA Clearance for RAMP® NT-proBNP Test II-71
PLAVIX® Receives FDA Nod II-72
Sanofi-aventis Wins FDA Approval to Use Lovenox in STEMI
Patients II-72
GlaxoSmithKline Receives FDA Approval for Arixtra Injection II-72
GlaxoSmithKline Wins EMEA Approval for Arixtra II-73
GlaxoSmithKline Wins MHLW Approval for Arixtra II-73
Ranbaxy Introduces Pravastatin Sodium 80mg Tablets in the US II-73
GlaxoSmithKline Introduces Coreg CRâ„¢ II-73

5. RECENT INDUSTRY ACTIVITY II-74
Pfizer Acquires Wyeth II-74
Sanofi-aventis Mexico Takes Over Laboratorios Kendrick II-74
Arca biopharma Merges with Nuvelo II-74
Merck Merges Business with Schering-Plough II-75
Portola Pharmaceuticals Enters into Partnership with Novartis II-75
Richter-Helm Signs Agreement with Athera Biotechnologies II-75
Daiichi Sankyo Sets Up Subsidiary II-76
Zydus Cadila Joins Forces with Eli Lilly for Cardiovascular
Drug Research II-76
AtCor Medical Enters into Contract with Pharmaceutical Company II-76
Takeda Acquires Millenium Pharmaceuticals II-76
Daiichi- Sankyo Acquires Controlling Stake in Ranbaxy II-77
GlaxoSmithKline Acquires Bristol Myers Squibb’s Egyptian
Business II-77
Shionogi Acquires Sciele Pharma II-77
GlaxoSmithKline Acquires Reliant Pharmaceuticals II-78
Recordati Acquires Yeni Ilac II-78
China Sky One to Take Over Heilongjiang Tianlong Pharmaceutical II-78
King Pharmaceuticals to Acquire Alpharma II-79
GlaxoSmithKline to Acquire Bristol-Myers Squibb Pakistan II-79
Meda Signs Deal to Take Over Roche Pharmaceutical Products II-79
Belupo and Farmavita Announce Merger II-79
Iroko Acquires Aggrastat’s Rights from Merck II-80
Biological E Collaborates with Choncept and Heparinex II-80
Merck Serono Signs Distribution Agreement with Bristol-Myers
Squibb II-80
BMS and KAI Sign Pact to Develop, Commercialize
Cardiovascular Drug II-80
CV Therapeutics and Menarini Group Sign Deal for Ranexa II-81
Forest Labs and Daiichi Sankyo Terminate Azor Co-Promotion
Agreement II-81
Daiichi Sankyo Submits Application for Antihypertensive Drug
Approval II-82
Daiichi Sankyo Establishes Subsidiary in Ireland II-82
PAION Announces Acquisition of Global Rights to Trigen’s
flovagatran II-82
Cardiovascular Systems Merges with Replidyne II-82
Amic Recieves Non-Exclusive License from Roche Diagnostics II-82
Iroko Pharmaceuticals Wins Rights to Aggrastat® II-83
Sepracor Acquires Oryx Pharmaceuticals II-83
GSK Acquires Reliant Pharmaceuticals II-83
Schering-Plough Takes Over Organon BioSciences II-84
Merck Serono and Bristol-Myers Squibb Ink Latin American
Distribution Deal II-84
Merck Acquires NovaCardia II-84
Bristol-Myers and Pfizer Ink Development and
Commercialization Agreements II-85
Inverness Acquires Biosite II-85
Siemens Acquires Diagnostic Division of Bayer Healthcare II-86
Siemens Announces Acquisition of Dade Behring II-86
Inverness Acquires Cholestech II-86
Sanofi-aventis Acquires Rights for Panaldine from Daiichi Sankyo II-86
Corautus Genetics and VIA Pharmaceuticals Sign Merger Agreement II-87
Alchemia Inks Marketing Alliance with Dr. Reddy’s for Heparin II-87
Recordati- Berlin Chemie Expand Licensing Agreement II-87

6. FOCUS ON SELECT GLOBAL PLAYERS II-88
Abbott Laboratories Inc. (US) II-88
AstraZeneca (UK) II-88
Bayer AG (Germany) II-89
Boehringer Ingelheim GmbH (Germany) II-89
Bristol-Myers Squibb Company (US) II-89
Daiichi Sankyo Company Limited (Japan) II-90
Dr. Reddy's Laboratories Ltd. (India) II-90
Eli Lilly and Company (US) II-91
F. Hoffmann-La Roche Ltd. (Switzerland) II-91
GlaxoSmithKline plc (UK) II-92
Inverness Medical Innovations, Inc. (US) II-92
Merck and Co., Inc. (US) II-93
Medicure Inc. (Canada) II-93
Novartis AG (Switzerland) II-93
Pfizer, Inc. (US) II-94
Wyeth (US) II-94
Sanofi-Aventis SA (France) II-95
Schering-Plough Corp. (US) II-95
Siemens Healthcare Diagnostics, Inc. (US) II-96
Takeda Pharmaceutical Company Limited (Japan) II-97
The Medicines Company (US) II-97


III. COMPETITIVE LANDSCAPE

Total Companies Profiled: 60 (including Divisions/Subsidiaries - 73)

------------------------------------------
Region/Country Players
------------------------------------------
The United States 34
Canada 5
Japan 6
Europe 20
France 1
Germany 7
The United Kingdom 3
Italy 2
Rest of Europe 7
Asia-Pacific (Excluding Japan) 6
Latin America 2
------------------------------------------

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

Analysis of the Global Infectious Disease Diagnostics Market

Analysis of the Global Infectious Disease Diagnostics Market

  • $ 10 000
  • Industry report
  • September 2014
  • by Frost & Sullivan

Molecular Methods Present Significant Opportunities This deliverable provides research and analysis of the global infectious disease diagnostics market. It includes an in-depth analysis of revenue forecast ...

OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018

OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018

  • $ 7 995
  • Industry report
  • June 2014
  • by Global Data

OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018 Summary Chronic lymphocytic leukemia (CLL), the most common form of adult leukemia, is caused by the uncontrolled ...

Frontier Pharma: Breast Cancer - Identifying and Commercializing First-in-Class Innovation

Frontier Pharma: Breast Cancer - Identifying and Commercializing First-in-Class Innovation

  • $ 6 995
  • Industry report
  • July 2014
  • by GBI Research

Frontier Pharma: Breast Cancer - Identifying and Commercializing First-in-Class Innovation Summary Exceptionally Large and Innovative Pipeline The breast cancer pipeline is the largest in the pharmaceutical ...

Bcc Research Bitopertin Forecast

August 2014 $ 5 500

1 Companies

Company Profiles

CytRx Corp.

United States

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.